Feature | June 13, 2013

Two Real-World Studies Demonstrate Positive Outcomes for MitraClip

Findings published demonstrate significant improvements in day-to-day quality of life and similar benefits in both elderly and younger patients

June 13, 2013 — Abbott announced publication of positive outcomes from two European post-approval studies of the catheter-based MitraClip therapy for the treatment of mitral regurgitation (MR). Results from ACCESS-EU, a European prospective study that enrolled 567 patients at 14 sites, have been published in the Journal of the American College of Cardiology. In addition, findings of the investigator-sponsored German TRAnscatheter Mitral Valve Interventions (TRAMI) registry, which enrolled 1,064 patients at 20 German sites, were recently published in EuroIntervention.

Abbott's MitraClip System, which received CE mark in 2008 and is commercially available in Europe and other international markets, is an investigational device in the United States. The device is delivered to the heart through the femoral vein and is designed to reduce MR by clipping together a portion of the leaflets of the mitral valve to allow the heart to more efficiently pump blood.

Data from ACCESS-EU demonstrated that in real-world, post-approval experience in Europe, patients undergoing the MitraClip therapy are predominantly high surgical risk, elderly patients who are mainly affected by functional MR, a type of MR in which a damaged heart impairs the performance of a normal mitral valve. ACCESS-EU showed that in this patient population, the MitraClip procedure demonstrated low rates of hospital mortality and adverse events and provided significant improvements in day-to-day quality of life at one year following treatment.

Findings of the ACCESS-EU study showed:

  • Most patients currently treated in Europe are high surgical risk. The mean age was 74 years, with 45 percent of patients older than 75 years. Most patients had secondary or functional mitral regurgitation (FMR), a type of MR in which a damaged heart impairs the performance of a normal mitral valve; low ejection fraction (most 40 percent or lower); and presented with multiple comorbidities, including coronary artery disease (63 percent), hypertension (76 percent), atrial fibrillation (68 percent) and renal disease (42 percent).
  • An implant success rate of 99.6 percent.
  • No incidence of death or stroke during the MitraClip procedure and in the immediate post-operative period.
  • A majority of patients (91.2 percent) achieved MR reduction to MR grade of 2+ or less (on a scale of 1+ [mild MR] to 4+ [severe MR]) at discharge (p<0.0001).
  • At one year following the procedure, 78.9 percent of patients were free from MR severity of 2+ or more (p<0.0001), and 71.4 percent of patients were in NYHA Functional Class II or Class I compared to 15 percent at baseline (p<0.0001).
  • A large majority of patients (79.2 percent) were discharged to home rather than to a skilled nursing facility.
  • Significant improvements in quality of life. At one year, Six-Minute Walk Test results, which measure distance walked on a flat, hard surface in a six-minute period, improved by a mean of 59.5 meters (p<0.0001). Minnesota Living With Heart Failure results, which measure the effects of symptoms, functional limitations and psychological distress on an individual's quality of life, improved by a mean 13.5 points (p<0.0001).

Results of the TRAMI registry showed similar benefits for the MitraClip therapy in both elderly and younger patients. To evaluate the influence of age, patients were divided into two subgroups: patients 76 years old and above, and patients younger than 76 years of age. The procedure proved to be safe in both groups. Hospital mortality was 2.9 percent in elderly patients and 2.8 percent in younger patients (p=0.96). Major adverse car diovascular or cerebrovascular events (MACCE), defined as a composite endpoint of death, myocardial infarction or stroke, was 3.5 percent vs. 3.4 percent (p=0.93) respectively. The majority of patients – 81.8 percent of elderly patients and 86.2 percent of younger patients (p=0.06) – fully recovered from the MitraClip procedure and were discharged without the need for nursing care. There was substantial relief of heart failure symptoms for the majority of patients, with comparable proportions of patients in NYHA Functional Class II or Class I (69.5 percent and 61.4 percent, respectively; p=n.s.).

For more information: www.abbott.com 

 

Related Content

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
News | Heart Valve Technology | January 15, 2019
Boston Scientific Corp. and Edwards Lifesciences Corp. announced that the companies have reached an agreement to settle...
The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as a arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital. Dr. Dominick Wiktor. The TEE is from a Philips Epiq system.

The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as an arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital.

Feature | Heart Valve Technology | January 14, 2019 | Allen Atchley, M.D., FACC, The Chattanooga Heart Institute
Mitral regurgitation (MR) is one of the most common types of heart valve diseases in the United States, affecting app
JC Medical Announces First U.S. Treatment With J-Valve TAVR Device
News | Heart Valve Technology | January 07, 2019
January 7, 2019 — JC Medical announced the successful treatment of the first U.S.
Edwards' Sapien 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Technology | Heart Valve Technology | January 02, 2019
Edwards Lifesciences Corp. announced that the Sapien 3 Ultra system has received U.S. Food and Drug Administration (FDA...
Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
Overlay Init